CY1692A - Use of ketone derivatives in the treatments of cognitive disorders - Google Patents

Use of ketone derivatives in the treatments of cognitive disorders

Info

Publication number
CY1692A
CY1692A CY169294A CY169294A CY1692A CY 1692 A CY1692 A CY 1692A CY 169294 A CY169294 A CY 169294A CY 169294 A CY169294 A CY 169294A CY 1692 A CY1692 A CY 1692A
Authority
CY
Cyprus
Prior art keywords
treatments
cognitive disorders
ketone derivatives
ketone
derivatives
Prior art date
Application number
CY169294A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868630075A external-priority patent/GB8630075D0/en
Priority claimed from GB878726424A external-priority patent/GB8726424D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CY1692A publication Critical patent/CY1692A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CY169294A 1986-12-17 1994-01-14 Use of ketone derivatives in the treatments of cognitive disorders CY1692A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868630075A GB8630075D0 (en) 1986-12-17 1986-12-17 Medicaments
GB878726424A GB8726424D0 (en) 1987-11-11 1987-11-11 Medicaments

Publications (1)

Publication Number Publication Date
CY1692A true CY1692A (en) 1994-01-14

Family

ID=26291706

Family Applications (1)

Application Number Title Priority Date Filing Date
CY169294A CY1692A (en) 1986-12-17 1994-01-14 Use of ketone derivatives in the treatments of cognitive disorders

Country Status (15)

Country Link
US (1) US4845115A (da)
EP (1) EP0275668B1 (da)
JP (1) JP2608078B2 (da)
KR (1) KR950013450B1 (da)
AU (1) AU618520B2 (da)
CY (1) CY1692A (da)
DE (1) DE3782028T2 (da)
DK (1) DK662687A (da)
ES (1) ES2052585T3 (da)
GR (1) GR3006255T3 (da)
HK (1) HK36693A (da)
IE (1) IE60991B1 (da)
IL (1) IL84845A0 (da)
NZ (1) NZ222950A (da)
PH (1) PH25025A (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200414A (en) * 1986-12-17 1993-04-06 Glaxo Group Limited Methods for the treatment of cognitive disorders
US5190954A (en) * 1986-12-17 1993-03-02 Glaxo Group Limited Methods for the treatment of cognitive disorders
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8820651D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
US5229407A (en) * 1988-09-01 1993-07-20 Glaxo Group Limited Medicaments
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
EP0492020A1 (en) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds for treating cognitive disorders
EP1022025A3 (en) * 1991-06-26 2002-06-05 Sepracor, Inc. Method and compositions for treating emesis nausea and other disorders using optically pure R(+) ondansetron
EP0591395A1 (en) * 1991-06-26 1994-04-13 Sepracor, Inc. Methods and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron
WO1994020102A2 (en) * 1993-03-08 1994-09-15 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating or preventing cerebrovascular diseases
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
PT1140090E (pt) * 1999-01-07 2005-05-31 Gerolymatos P N Sa Utilizacao de fanquinona para o tratamento ou prevencao da perda de memoria
JP2002538102A (ja) * 1999-03-01 2002-11-12 セプラコア インコーポレーテッド 光学的に純粋なｒ（＋）オンダンセトロンを使用する無呼吸および無呼吸障害の治療方法
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
GB0701970D0 (en) 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI74707C (fi) * 1982-06-29 1988-03-10 Sandoz Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror.
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
NO164025C (no) * 1984-01-25 1990-08-22 Glaxo Group Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-imidazolylmetyl-tetrahydrokarbazolon-derivater.
DE3680123D1 (en) * 1985-01-23 1991-08-14 Glaxo Group Ltd Tetrahydrocarbazolonderivate.
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
EP0405617A3 (en) * 1985-03-14 1992-11-25 Beecham Group P.L.C. Medicaments for the treatment of anxiety
US4624961A (en) * 1985-04-17 1986-11-25 A. H. Robins Company, Incorporated Method for enhancing memory or correcting memory deficiency with arylamidopyrazolidines and arylamidodiazabicycloalkanes
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
HU202108B (en) * 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol

Also Published As

Publication number Publication date
DE3782028D1 (de) 1992-11-05
DK662687A (da) 1988-06-18
JPS63253083A (ja) 1988-10-20
KR950013450B1 (ko) 1995-11-08
PH25025A (en) 1991-01-28
NZ222950A (en) 1997-06-24
IE60991B1 (en) 1994-09-07
EP0275668A3 (en) 1989-10-11
EP0275668A2 (en) 1988-07-27
JP2608078B2 (ja) 1997-05-07
US4845115A (en) 1989-07-04
DK662687D0 (da) 1987-12-16
AU8261487A (en) 1988-06-23
IE873414L (en) 1988-06-17
IL84845A0 (en) 1988-06-30
GR3006255T3 (da) 1993-06-21
AU618520B2 (en) 1992-01-02
DE3782028T2 (de) 1993-02-18
ES2052585T3 (es) 1994-07-16
HK36693A (en) 1993-04-23
EP0275668B1 (en) 1992-09-30
KR880007074A (ko) 1988-08-26

Similar Documents

Publication Publication Date Title
GB8600822D0 (en) Treatment of skin disorders
EP0204597A3 (en) Use of alfuzosine in the treatment of urinary affections
EP0326034A3 (en) Combination for the treatment of nervous cells and fibers illnesses and disorders
AU6896487A (en) Hair treatment agent
CY1692A (en) Use of ketone derivatives in the treatments of cognitive disorders
ZA855916B (en) Treatment of skin disorders
PL268262A1 (en) Weedicidal specific and the method of manufacturing of new derivatives of 2-benzoylcyclohexandion-1,3
PT84704A (en) Thiolactam-n-acetic derivatives their production and use
AU624067B2 (en) Preparation suitable for use in the treatment of enteric disorders
GB8625912D0 (en) Thermochemical treatment
EP0255801A3 (en) Anilinotriazines and their use
PL266144A1 (en) Weedicidal specific and the method of manufacturing of new derivatives of 3-amino-2-benzoylcyclohexene-2-ane-1
PL266143A1 (en) Weedicidal specific and the method of manufacturing of new derivatives of 2-benzoylcyclohexene-2-ane-1
EP0267404A3 (en) Use of praziquantel for the topical treatment of helminthiasis in cats
GB2203645B (en) Improvements in the treatment of hair
GB2176104B (en) Compositions for treatment of the hair and scalp.
AU4096789A (en) The use of lactam derivatives in the treatment of cognitive disorders
EP0238357A3 (en) 1,2,4-triazinone derivatives, their preparation and use
GB8715914D0 (en) Treatment of cerabral disorders
PL266142A1 (en) Weedicidal specific and the method of manufacturing of new derivatives of 2-phenylaceto-cyclohexanotrion-1,3,5
EP0407016A3 (en) Use of benzodioxinopyrrole derivatives in the treatment of anxiety
EP0267537A3 (en) Process for the preparation of vinylglyoxal derivatives, vinylglyoxal derivatives and their use
SG4695G (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney-diseases
ZA893606B (en) Use of diazepinones for treating disorders of the microcirculation
GR871634B (en) Therapeutic mean and its usage